Accessibility Statement
1. Our commitment to accessibility
Elixier Diagnostics (c/o JRS Ltd) is committed to making its website as accessible as possible so that everyone, including people with disabilities, can access information about our diagnostic imaging and related healthcare services.
We aim to meet the Web Content Accessibility Guidelines (WCAG) 2.2 Level AA where reasonably practicable. We also recognise our duties under the Equality Act 2010 to make reasonable adjustments for disabled people.
2. How accessible this website is
We want as many people as possible to be able to use this website. For example, you should be able to:
- Navigate most of the site using only a keyboard
- Zoom in up to 400% without text spilling off the screen (where supported)
- Use most of the site with a screen reader
- Use common browser and device accessibility tools
We know some parts of this website are not fully accessible. These are explained below.
3. Feedback and contact information
If you have difficulty using any part of this website or need information in a different format (such as large print, easy read, audio or braille), please contact us:
Email: contact@elixierdiagnostics.uk
Phone: 01772 356631
Post: Elixier Diagnostics, Unit 5, Ground Floor, Fairways Park, Fulwood, Preston, PR2 9LF
Please include the page URL, a brief description of the issue, and details of your device, browser, and any assistive technology used.
We aim to acknowledge requests within 2 working days and respond within 5 working days.
4. Enforcement procedure (UK users)
If you are not satisfied with our response, you can contact the Equality Advisory and Support Service (EASS):
Website: https://www.equalityadvisoryservice.com
Telephone: 0808 800 0082
5. Technical information about this website’s accessibility
Elixier Diagnostics is committed to making this website accessible in line with WCAG 2.2 Level AA, where reasonably practicable.
Compliance status: This website is currently partially compliant with WCAG 2.2 AA due to the issues listed below.
Elixier Diagnostics is not a public sector body. While the Public Sector Bodies Accessibility Regulations may not apply, we use them as best practice.
6. Non-accessible content
6.1 Non-compliance with accessibility good practice
- Some images and icons may not yet have descriptive alternative text
- Some link text may not be fully descriptive when read out of context
- Some form fields may not be correctly associated with labels
- Colour contrast may be insufficient in certain combinations
- Some PDF documents may not be fully accessible to screen readers
We plan to address high-priority issues and publish an updated statement by 30 September 2026.
6.2 Disproportionate burden
We do not currently claim that any accessibility improvements represent a disproportionate burden. Alternative formats will be provided on request where needed.
6.3 Content not within scope
Some third-party content is not fully within our control. We choose accessible providers where reasonably possible.
7. What we’re doing to improve accessibility
- Reviewing templates and components against WCAG 2.2 AA
- Improving headings, link text and form labels
- Adding meaningful alternative text to images
- Checking and improving colour contrast
- Including accessibility checks in future development
- Providing guidance to staff who edit website content
8. How we tested this website
This website was last reviewed on 28 January 2026 by Elixier Diagnostics.
- Automated testing on key pages
- Manual keyboard-only navigation testing
- Screen-reader spot checks on common user journeys
We plan to commission an external accessibility audit when major changes are made or at least every two years.
9. Preparation of this accessibility statement
This statement was prepared and last reviewed on 28 January 2026. It will be reviewed at least annually.
10. How this fits with GDPR
While accessibility statements are not a direct UK GDPR requirement, accessibility supports transparency and fairness by ensuring all users can access information about how we process personal data and exercise their rights.